





# Financial Highlights


**Revenue doubled to £3.1m**  
(H1 2004: £1.5m)




**Cash at bank 31 March 2005 £2.6m**  
(30 Sept 2004: £3.2m)



**Loss before tax halved to £0.6m**  
(H1 2004: £1.2m loss)



**Cash outflow (before tax and financing) £0.5m**  
(H1 2004: £3.5m outflow)



30 June 2005: Total contracted forward business £4.6m of which £3.1m deliverable in H2 2005

# Chairman's Statement

The recovery demonstrated in the second half of the previous financial year has continued during the six months to 31 March 2005, with a 50% increase in turnover over that period. At £3.1m turnover is double the level achieved in the same period last financial year (H1 2004: £1.5m). This trend is continuing with contracted business for the second half of this financial year currently standing at £3.1m.

The loss before tax for the six months to 31 March 2005 was £0.6m (H1 2004: £1.2m loss) and the cash outflow for the period was also £0.6m (H1 2004: £3.5m outflow), which resulted in a closing cash at bank (including short term deposits) of £2.6m.

This positive trend can be attributed to the movement of the Group's business towards protein production, which tripled and represented 42% of turnover in the first six months to 31 March 2005 (H1 2004: 23%) and virus production, which has doubled and represented 32% of turnover (H1 2004: 35%), together with a concentration of Cobra's sales effort in North America. This territory generated 70% of turnover in the period (H1 2004: 31%) and reflects the reality of global demand for biopharmaceuticals, which is dominated by the US, where Cobra will continue to strengthen its focus. The Group's total contracted forward business now stands at £4.6m including £1.5m for the financial year 2006 and this level of activity will require additional production staff at both the Keele and the Oxford facilities to ensure we meet customers' timescales.

A broader offering to our customers is also important and in this regard we have entered into an alliance with Synco BioPartners of Amsterdam to provide access to Phase III facilities and the commercial supply of certain products thereby increasing our ability to win long term contracts. We have also recently submitted an application to extend our licence to allow Cobra to provide 'fill and finish' services from the Oxford Facility, which is currently under review by the MHRA. Other ways to further increase our capability in providing 'fill and finish' are also being considered.

Cobra's longer term objective is to be among the leading providers of specialist bio-manufacturing in the global marketplace. Clearly, to achieve this will require organic growth, which can be provided from both the Keele and Oxford facilities where we are planning to increase capacity, but also through corporate development to further increase our service offering. Management is actively engaged in reviewing a number of opportunities to determine the optimum way forward, once we have delivered on our immediate financial targets, which are of course a prerequisite for investor confidence.

Thanks to the efforts of all our staff, Cobra has matured over the past twelve months, responding to the challenges of the marketplace by focusing on the protein and virus market and North America, and as a consequence is now much stronger and more competitive. The contracted forward order book confirms this for both the second half of this financial year and the start of the next financial year, bringing Cobra back into line with its objectives, which are to be a profitable and a leading supplier to the global biopharmaceutical industry.




G. Peter Fothergill  
Chairman  
30 June 2005

# Operational Highlights

“Cobra has matured over the past twelve months, responding to the challenges of the marketplace by focusing on the protein and virus markets and North America, and as a consequence is now much stronger and more competitive.”

**North American revenue quadrupled to £2.1m (H1 2004: £0.5m)**




## Revenue by destination (% of total)

	H1 2005	H1 2004
North America	70%	31%
UK	26%	57%
Europe and RoW	4%	12%

**Protein revenue tripled to £1.3m (H1 2004: £0.4m)**

**Virus revenue doubled to £1.0m (H1 2004: £0.5m)**



## Revenue by product (% of total)

	H1 2005	H1 2004
Protein	42%	23%
Virus	32%	35%
DNA	19%	34%
Cell Line	7%	8%

**March 2005:** ORT-VAC oral vaccine platform validated in a pre-clinical plague model

**May 2005:** Cobra enters into an alliance with Synco BioPartners of Amsterdam to provide access to Phase III and commercial supply

**June 2005:** Application made by Cobra to provide ‘fill and finish’ services from the Oxford Facility, currently under review by the MHRA

# Chief Executive's Statement

The value we bring to our customers is based on innovation and a commitment to maintain the highest quality standards in the industry. After our setbacks in the financial year 2004, the six months to 31 March 2005 were the most successful in the Group's history in terms of securing contracted business. As a result turnover reached £3.1m (H1 2004 £1.5m) and total contracted forward business currently stands at £4.6m, £3.1m of which is deliverable in the second half of the financial year 2005. To meet this increasing demand the Group is engaged in a modest expansion programme focussed mainly on our new £4.8m Oxford Facility.

This turnaround has been due to three factors:

1. The Group's focus on sales and marketing in the US market;
2. An increased demand for specialist manufacturing services in both the protein and virus sectors; markets to which Cobra's knowledge base and facilities are well suited;
3. Stabilisation in the DNA market. Demand, although much lower than in previous years, continues at a level where a sustainable contribution can be made.

We believe that, provided the appetite for investment in small to medium biotech product development companies (Cobra's major client base, historically 90% of turnover) is maintained, Cobra's recovery and expansion will continue.

**The importance of the North American market:** The US continues to dominate the worldwide biotechnology industry both in terms of technical achievement and investor interest. In this current period North America generated turnover of £2.1m or 70% of the total (H1 2004: £0.5m). Cobra now has three sales staff operating in North America centred in the biotechnology hubs of the West Coast, Mid West and East Coast of the US.

Given our location the UK and the rest of Europe remain important potential markets for Cobra and recently we have seen stable demand for our services in these territories, with combined turnover of £0.9m in the first six months of the financial year 2005 (H1 2004: £1.0m).

**Protein manufacture:** Protein products dominate the world market for biopharmaceuticals and Cobra has a great deal of technical experience in the development of both microbial and mammalian protein products and turnover for the six months to 31 March 2005 has tripled to £1.3m (H1 2004: £0.4m). This is a remarkable success given our scale of operations and despite this, Cobra is successfully building a track record in protein products by offering specialised manufacturing services, where:

- Our scale of operation is compatible with our customers' requirements
- The production cell line is non-standard and development requires an innovative approach

**Virus manufacture:** Virus turnover for the six months to 31 March 2005 doubled to £1.0m (H1 2004: £0.5m). Demand for the manufacture of virus products remains healthy with major

programmes undertaken with Reovirus (Oncolytics Inc) and Herpes simplex virus as well as the continued support of two recombinant adenovirus based treatments for prostate cancer. Virus manufacture is a niche requiring very specialised manufacturing facilities and techniques. Cobra's capacity and experience enables us to support our customers' programmes through their product's lifecycle and enables us to compete strongly in a small but potentially lucrative market.

**DNA manufacture:** In the first six months to 31 March 2005 DNA manufacture was at a similar level to 2004 with £0.6m of turnover. The short term outlook for DNA manufacturing is likely to be static until more efficient delivery systems and formulations are adopted for DNA vaccines. Gross margins on DNA manufacturing are also under pressure from increased competition and the increasing rigour in cleaning validation (contaminants of less than 1 part per trillion are detectable in DNA products).

Currently the Group does not have the scale to take a DNA product through to Phase III and commercial scale manufacture. In order to enable seamless commercialisation of our customers' products Cobra has concluded an agreement with Synco BioPartners ("Synco") in the Netherlands. Under this agreement Cobra has licensed Synco (on a product by product basis) to manufacture our clients products at commercial scale using Cobra's proprietary processes.

**Cell Line manufacture:** Programmes with Advaxis Inc, involving Listeria and the Ludwig Institute for Cancer Research both continued in the six months to 31 March 2005, generating £0.2m turnover (H1 2004: £0.1m). Cobra is also developing its own product development platform, called ORT-VAC in collaboration with DSTL (UK Defence Science and Technology Laboratory at Porton Down). Earlier in the year Cobra and DSTL scientists jointly published a paper in the prestigious 'peer reviewed' journal *Infection and Immunity* demonstrating that in a pre-clinical model a single dose of an ORT-VAC based vaccine could protect against a lethal plague challenge.

**Outlook for Cobra's services:** In the markets we focus in, Cobra's offering is strong and generates a high level of repeat business when the customer base is well funded. After setbacks in the financial year 2004 when a number of our customers experienced severe funding difficulties and the DNA market slumped, we reacted by increasing our sales and marketing effort and have continued to build new business at an unprecedented rate over the past twelve months. We hope that this trend will be maintained and with a cautious expansion programme planned, the Group's scale of operations will continue to grow towards capacity during the next financial year.

David Thatcher  
Chief Executive  
30 June 2005



# Group Profit and Loss Account

for the Half Year Ended 31 March 2005

	Notes	Unaudited 6 months ended 31 March 2005 £	Unaudited 6 months ended 31 March 2004 £	Year ended 30 September 2004 £
Turnover	2	3,055,015	1,529,751	3,516,351
Cost of sales		(1,499,693)	(930,085)	(1,951,044)
<b>Gross profit</b>		<b>1,555,322</b>	599,666	1,565,307
Other operating costs		(2,174,684)	(1,922,374)	(3,949,372)
<b>Loss on ordinary activities before interest and taxation</b>		<b>(619,362)</b>	(1,322,708)	(2,384,065)
Bank interest receivable		56,311	98,500	177,260
Interest payable		(74,944)	(15,188)	(64,370)
<b>Loss before tax</b>		<b>(637,995)</b>	(1,239,396)	(2,271,175)
Taxation	3	21,072	(50,500)	(126,675)
<b>Retained loss for the period</b>	5	<b>(616,923)</b>	(1,289,896)	(2,397,850)
<b>Loss per share</b>				
Basic	4	(3.2)p	(6.6)p	(12.3)p
Diluted	4	(3.2)p	(6.6)p	(12.3)p

## Group Statement of Total Recognised Gains and Losses

There were no recognised losses or gains other than the loss for the period/year.

# Group Balance Sheet

as at 31 March 2005

	Notes	Unaudited 6 months ended 31 March 2005 £	Unaudited 6 months ended 31 March 2004 £	Year ended 30 September 2004 £
<b>Fixed assets</b>				
Tangible assets		6,937,059	6,559,043	7,168,024
		<b>6,937,059</b>	6,559,043	7,168,024
<b>Current assets</b>				
Stocks and work in progress		236,617	213,869	275,504
Debtors		1,584,893	1,739,053	1,591,730
Cash at bank and in hand		2,603,600	3,752,066	3,158,573
		<b>4,425,110</b>	5,704,988	5,025,807
<b>Creditors: amounts falling due within one year</b>		<b>(2,069,192)</b>	(1,956,480)	(2,203,797)
<b>Net current assets</b>		<b>2,355,918</b>	3,748,508	2,822,010
<b>Total assets less current liabilities</b>		<b>9,292,977</b>	10,307,551	9,990,034
<b>Creditors: amounts falling due after more than one year</b>		<b>(1,756,743)</b>	(1,048,440)	(1,838,877)
<b>Net assets</b>		<b>7,536,234</b>	9,259,111	8,151,157
<b>Capital and reserves</b>				
Called up share capital	5	1,950,727	1,950,000	1,950,000
Share premium	5	9,633,766	9,632,493	9,632,493
Merger reserve	5	29,728,872	29,728,872	29,728,872
Profit and loss account	5	(33,777,131)	(32,052,254)	(33,160,208)
<b>Equity shareholders' funds</b>		<b>7,536,234</b>	9,259,111	8,151,157

# Group Statement of Cash Flows

for the Half Year Ended 31 March 2005

	Notes	Unaudited 6 months ended 31 March 2005 £	Unaudited 6 months ended 31 March 2004 £	Year ended 30 September 2004 £
<b>Net cash outflow from operating activities</b>	<b>6</b>	<b>(223,762)</b>	(1,701,298)	(2,014,490)
<b>Returns on investments and servicing of finance</b>				
Interest received		56,311	98,500	177,260
Interest on bank loans		(36,336)	–	(11,441)
Interest element of finance lease payments		(38,608)	(15,188)	(52,929)
		<b>(18,633)</b>	83,312	112,890
<b>Taxation</b>				
R&D tax credit		69,189	323,278	323,278
<b>Capital expenditure</b>				
Payments to acquire tangible fixed assets		(258,305)	(1,932,122)	(3,179,500)
<b>Net cash outflow before the management of liquid resources and financing</b>		<b>(431,511)</b>	(3,226,830)	(4,757,822)
<b>Management of liquid resources</b>				
Decrease in short term deposits		675,379	3,084,405	3,765,226
<b>Financing</b>				
Issue of ordinary shares		2,000	–	–
Repayment of long term loans		(39,321)	–	(19,861)
Repayment of capital element of finance leases		(173,081)	(282,855)	(451,661)
Lease finance acquired		86,940	–	1,126,166
		<b>(123,462)</b>	(282,855)	654,644
<b>Increase/(decrease) in cash</b>	<b>7</b>	<b>120,406</b>	(425,280)	(337,952)

# Reconciliation of Net Cash Flow to Movement in Net Funds

for the Half Year Ended 31 March 2005

	<b>Unaudited 6 months ended 31 March 2005 £</b>	Unaudited 6 months ended 31 March 2004 £	Year ended 30 September 2004 £
<b>Increase/(decrease) in cash</b>	<b>120,406</b>	(425,280)	(337,952)
Repayment of long term loans	<b>39,321</b>	–	19,861
Repayment of capital element of finance leases	<b>173,081</b>	282,855	451,661
Lease finance acquired	<b>(86,940)</b>	–	(1,126,166)
Cash inflow from short term deposits	<b>(675,379)</b>	(3,084,405)	(3,765,226)
<b>Movement in net funds during the period</b>	<b>(429,511)</b>	(3,226,830)	(4,757,822)
Net funds at the start of the period	<b>917,112</b>	5,674,934	5,674,934
Net funds at the end of the period	<b>487,601</b>	2,448,104	917,112

# Notes to the Unaudited Results

for the Half Year Ended 31 March 2005

## 1 INTERIM ACCOUNTS

The Group's Interim Results consolidate the results of the Company and its subsidiary company made up to 31 March 2005.

The interim financial information has been prepared on the basis of the accounting policies set out in the Group's financial statements for the year ended 30 September 2004. The financial information contained in this interim statement does not constitute statutory accounts as defined in the Companies Act 1985. The financial information for the full preceding year is based on the financial statements for the financial year ended 30 September 2004. These accounts, upon which the auditors issued an unqualified opinion, have been delivered to the Registrar of Companies.

The Board of Directors approved the Interim Report on 30 June 2005.

## 2 TURNOVER

The Group operates in one principal area of activity, that of contract manufacture.

All turnover originates from the UK. The geographical analysis of turnover by destination is as follows:

	<b>Unaudited 6 months ended 31 March 2005 £</b>	Unaudited 6 months ended 31 March 2004 £	Year ended 30 September 2004 £
<b>Continuing</b>			
United Kingdom	<b>786,136</b>	862,922	1,992,637
North America	<b>2,130,379</b>	475,777	1,096,887
Europe	<b>111,384</b>	110,581	262,990
Rest of the World	<b>27,116</b>	80,471	163,837
	<b>3,055,015</b>	1,529,751	3,516,351

## 3 TAXATION

The Group is entitled to Research and Development tax relief under Schedule 20 of the Finance Act 2000, in respect of the period ended 31 March 2005.

	<b>Unaudited 6 months ended 31 March 2005 £</b>	Unaudited 6 months ended 31 March 2004 £	Year ended 30 September 2004 £
<b>Taxation on loss on ordinary activities</b>			
<b>Current tax:</b>			
Tax credit in relation to R&D claim	<b>(16,794)</b>	(34,500)	(64,910)
Adjustments in respect of previous periods	<b>(4,278)</b>	–	(33,415)
<b>Total current tax</b>	<b>(21,072)</b>	(34,500)	(98,325)
<b>Deferred tax:</b>			
Origination & reversal of timing differences	–	85,000	225,000
<b>Total deferred tax</b>	–	85,000	225,000
<b>Total tax</b>	<b>(21,072)</b>	50,500	126,675

# Notes to the Unaudited Results

for the Half Year Ended 31 March 2005

## 4 LOSS PER ORDINARY SHARE

The calculation of basic loss per ordinary share is based on losses of £616,923 (six months ended 31 March 2004: £1,289,896 loss; year ended 30 September 2004: £2,397,850 loss) and on 19,501,239 ordinary shares (six months ended 31 March 2004: 19,500,000; year ended 30 September 2004: 19,500,000) being the weighted average number of shares in issue during the period.

The loss for the period and the weighted average number of ordinary shares for calculating the diluted loss per share for the period ended 31 March 2005 are identical to those used for the basic loss per share. This is because the outstanding share options and warrants would have the effect of reducing the loss per ordinary share and would therefore not be dilutive under the terms of Financial Reporting Standard ("FRS") No 14.

## 5 RECONCILIATION OF SHAREHOLDERS' FUNDS AND MOVEMENT ON RESERVES

	Share Capital £	Share Premium £	Merger Reserve £	Profit and Loss Account £	Total £
As at 30 September 2004	1,950,000	9,632,493	29,728,872	(33,160,208)	8,151,157
Issue of ordinary shares	727	1,273	–	–	2,000
Loss for the period	–	–	–	(616,923)	(616,923)
<b>As at 31 March 2005</b>	<b>1,950,727</b>	<b>9,633,766</b>	<b>29,728,872</b>	<b>(33,777,131)</b>	<b>7,536,234</b>

## 6 RECONCILIATION OF OPERATING LOSS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	Unaudited 6 months ended 31 March 2005 £	Unaudited 6 months ended 31 March 2004 £	Year Ended 30 September 2004 £
Operating loss	(619,362)	(1,322,708)	(2,384,065)
Depreciation of tangible fixed assets	349,334	160,886	391,946
Decrease/(increase) in stock	38,887	(6,950)	(68,585)
(Increase)/decrease in debtors	(56,943)	361,334	347,034
Increase/(decrease) in creditors	64,322	(893,860)	(300,820)
<b>Net cash outflow from operating activities</b>	<b>(223,762)</b>	<b>(1,701,298)</b>	<b>(2,014,490)</b>

# Notes to the Unaudited Results

for the Half Year Ended 31 March 2005

## 7 ANALYSIS OF NET MOVEMENT IN NET FUNDS

	1 October 2004 £	Cash Flow £	31 March 2005 £
Cash at bank and in hand	145,835	120,406	<b>266,241</b>
Short term deposits *	3,012,738	(675,379)	<b>2,337,359</b>
	<b>3,158,573</b>	<b>(554,973)</b>	<b>2,603,600</b>
Bank loan	(1,067,639)	39,321	<b>(1,028,318)</b>
Finance leases	(1,173,822)	86,141	<b>(1,087,681)</b>
	<b>917,112</b>	<b>(429,511)</b>	<b>487,601</b>

The majority of finance leases are arranged in respect of sale and leaseback transactions. Accordingly new finance leases are shown as a separate component of cash flow in the cash flow statement.

\* Short term deposits are included within the cash at bank and in hand on the balance sheet.

## 8 POST BALANCE SHEET EVENTS

On 3 May 2005 the Group agreed to purchase additional land and a new building adjacent to the Oxford Facility for a total consideration of £730,000. The initial payment of £235,000 was made on the 3 May 2005 with the balance due on completion expected in November 2005.

On 28 April 2005 the Group took out a £1.8 million mortgage facility with National Westminster Bank Plc, replacing the existing £1.1m mortgage with HSBC Bank Plc and providing the additional funding for the £730,000 land and building acquisition. The loan is repayable monthly over a 15 year period, with an initial two years capital repayment holiday. The rate of interest payable is 1.5% over National Westminster Bank Plc base rate.

# Independent Review Report to Cobra Biomanufacturing Plc

## Introduction

We have been instructed by the Company to review the financial information for the six months ended 31 March 2005, which comprises such as the Group Profit and Loss Account, Statement of Total Recognised Gains and Losses, Group Balance Sheet, Group Statement of Cash Flows, and the related notes 1 to 8. We have read the other information contained in the interim report and considered whether it contains any apparent misstatements or material inconsistencies with the financial information.

This report is made solely to the Company in accordance with guidance contained in Bulletin 1999/4 'Review of interim financial information' issued by the Auditing Practices Board. To the fullest extent permitted by the law, we do not accept or assume responsibility to anyone other than the Company, for our work, for this report, or for the conclusions we have formed.

## Directors' responsibilities

The interim report, including the financial information contained therein, is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the interim report as required by the AIM Rules issued by the London Stock Exchange.

## Review work performed

We conducted our review having regard to the guidance contained in Bulletin 1999/4 'Review of interim financial information' issued by the Auditing Practices Board for use in the United Kingdom. A review consists principally of making enquiries of Group management and applying analytical procedures to the financial information and underlying financial data, and based thereon, assessing whether the accounting policies and presentation have been consistently applied, unless otherwise disclosed. A review excludes audit procedures such as tests of controls and verification of assets, liabilities and transactions. It is substantially less in scope than an audit performed in accordance with United Kingdom Auditing Standards and therefore provides a lower level of assurance than an audit. Accordingly we do not express an audit opinion on the financial information.

## Review conclusion

On the basis of our review we are not aware of any material modifications that should be made to the financial information as presented for the six months ended 31 March 2005.

**Ernst & Young LLP**  
**Manchester**  
**30 June 2005**



# Shareholder Information

## Share Price Information

The Company's share price is available from the website of Cobra Biomanufacturing Plc under: [www.cobrabio.com](http://www.cobrabio.com)

## Company Web Site

The Company's website provides information on products, activities and financial information. It includes latest financial information and press releases and any other information that is relevant to the Company.

## Shareholder Enquiries

Any queries regarding individual shareholdings, transfers etc, should be directed to Capita Registrars.

Shareholders wishing to consolidate two or more individual certificates may do so by writing to Capita Registrars, enclosing the certificates to be consolidated.

Where shareholders are receiving duplicate sets of accounts or mailing, as a result of inconsistencies in the name or address details, they should advise the registrars so that this can be corrected.

## Investor Relations Services

The Company operates an Investor Relations Mailing List and Email Alert Service for investors and other interested parties.

Copies of announcements made during the year as well as the annual and interim reports are sent to current registered shareholders. However, if you would like to receive this information regardless of your current shareholding, you can register for either one of the above services by writing to Investor Relations, Cobra Biomanufacturing Plc, Stephenson Building, The Science Park, Keele, Staffordshire ST5 5SP.

Alternatively, you can register to receive updates electronically via the website under: [www.cobrabio.com/investors/investor\\_email\\_alert.htm](http://www.cobrabio.com/investors/investor_email_alert.htm)

## Data Protection Policy

We will comply with the requirements of all Data Protection legislation in force in England and Wales from time to time. In particular, you may request a copy of any personal data held by us about you upon written request. Please note that we reserve the right to charge the current statutory fee for providing such information.

We do not use or distribute the information provided by you to our Investor Relations Mailing List or Email Alert Service, for any purpose other than the provision to you of up to date company information. We do not sell databases or personal information to third parties.

You can request to be removed from the mailing lists at any time, by writing to the registered office or via email.



## Glossary of Terms

**Biopharmaceuticals** – medicines where the active principal cannot be chemically synthesised and comprise either recombinant DNA, protein or virus.

**Cell line** – live cells as medicinal products.

**Cobra** – Cobra Biomanufacturing Plc and its wholly owned subsidiary Cobra Biologics Limited (“The Group”).

**DNA** – Deoxyribonucleic Acid, a molecule that encodes genetic information.

**GMP** – Good Manufacturing Practice, a code of practice that ensures medicinal products are produced consistently and to the appropriate quality standards. In the UK, manufacturers of medicinal products require accreditation with the Medicines and Healthcare products Regulatory Agency (“MHRA”).

**Herpes simplex virus** – a family of viruses that contain DNA which are responsible for a number of conditions, including chickenpox and oral herpes.

**ORT®** – Operator Repressor Titration, a host vector system that avoids the use of antibiotics and antibiotic resistant genes during biological manufacture.


**ORT-VAC** – derived using ORT® technology: strains of attenuated bacteria bearing high copy number plasmids for use as live vaccines.

**Plasmid DNA** – vaccines/medicines where the active ingredient is made of DNA produced in bacteria and which encodes a therapeutic gene, with Plasmid DNA being replicating circular DNA encoding genes.

**Protein products/manufacture** – medicines (the manufacture of medicines), where the active ingredient is protein.

**Reovirus** – the Respiratory Enteric Orphan Virus, an RNA (ribonucleic acid) virus, whose genetic information is stored in RNA. A non-pathogenic variant of this virus could be used to kill some forms of cancer cells.

**Virus products/manufacture** – medicines (the manufacture of medicines) where the active ingredient is a recombinant virus engineered to deliver DNA encoding a therapeutic gene.



## **Cobra Biomanufacturing Plc**

**Registered Office**  
Stephenson Building  
The Science Park  
Keele  
Staffordshire  
ST5 5SP  
UK

Tel: +44(0) 1782 714181  
Fax: +44(0) 1782 710485  
[www.cobrabio.com](http://www.cobrabio.com)